Hutchmed China Ltd.

Hutchmed China Ltd. is a biopharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of novel therapies targeting oncology and immunological diseases. It operates a diverse business model with a robust pipeline of innovative cancer drugs and a commercial platform that distributes a broad portfolio of prescription and consumer health products across China. Hutchmed’s research and development efforts focus on targeted therapies and immunotherapies, covering a range of cancers and progressing through global clinical trials. The company is recognized for its scientific innovation, with key products such as FRUZAQLA driving substantial revenue growth in its oncology segment. Financially, Hutchmed maintains a strong balance sheet and continues to deliver profitable operations and sustainable growth, propelled by both effective cost management and strategic partnerships. Its role in the financial markets is significant as a representative of China’s growing biopharmaceutical sector and as a conduit for global investors seeking exposure to innovations in healthcare and life sciences.